6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of articaine hydrochloride with epinephrine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a casual relationship to drug exposure. Persistent parestreatiseis of the lips, tongue, and oral tissues have been reported with use of articaine of articaine hydrochloride, with slow, incomplete, or no recovery. These postmarketing events have been reported with use of articaine, especially in pediatric age groups, shich is usually reversible. Prolonged numbers can result in soft tissue injuries such as that of the lips and tongue in these age groups. Ischemic injury and necrosis has been described following use of articaine and has been postulated to be due to vascular spasm of terminal arterial branches. Praralysis of ocular muscles has been reported, especially in posterior, superior alveolar injections of articaine during dential anesthesia. Symptoms include diplopia, mydriasis, ptosis and difficulty in abduction of the affected eye. These symptoms have been described as developing immediately after injection of the anesthetic solution and persisting one minute to several hours, with enerally complete recover. inute to several hours, with generally complete recovery. and persisting one minute to 7 DRUG INTERACTIONS

7 DRUG INTERACTIONS The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-admenergic antagonists or tricyclic antidepressants may produce severe, prolonged hypertension. Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential [see Warnings and Precautions (5.1)]. Patient that are administered local anesthetics may be at increased risk of developing methemoglobinemia when concurrently exposed to the

## following oxidizing agents:

Class	Examples
Nitrates/Nitrites	nitroglycerin, nitroprusside, nitric oxide, nitrous oxide
Local anesthetics	benzocaine, lidocaine, bupivacaine, mepivacaine, tetracaine, prilocaine, procaine, articaine
Antineoplastic agents	cyclophosphamide, flutamide, rasburicase, isofamide, hydroxyurea
Antibiotics	dapsone, sulfonamides, nitrofurantoin, para-aminosalicylic acid
Antimalarials	chloroquine, primaquine
Anticonvulsants	phenytoin, sodium valproate, phenobarbital
Other drugs	acetaminophen, metoclopramide, sulfa drugs (i.e., sulfasalazine), quinine

## 8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy Teratogenic Effects-Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women with articaine with Teratogenic Effects-Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women with articaine with Teratogenic Éffects-Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women with articaine with epinephrine. Articaine hydrochloride and epinephrine (1:100,000) has been shown to increase fetal deaths and skeletal variations in rabbits when given in doses approximately 4 times the maximum recommended human dose (MRHD). Crabloc® should be used during pregnancy only ffle potential benefit justifies the potential risk to the fetus. In embry-fetal toxicity studies in rabbits, MeRHD, based on body surface area) caused fetal death and increased fetal skeletal variations, but these effects may be attributable to severe maternal toxicity, including seizures, observed at this dose. In contrast, no embryo-fetal toxicities were observed when articaine and epinephrine (1:100,000) was administerd subcutaneously throughout organogenesis at doese up to 40 mg/kg in rabbits and 80 mg/kg in rats (approximately 2 times the MRHD based on body surface area). In pre- and postnatal developmental studies subcutaneous administration of articaine hydrochloride to pregnant rats throughout gestation and adversely affected passive avoldance, a measure of learning, in pugs. This does also produced severe maternal toxicity is nome animas. A dose of 40 mg/kg (approximately 2 times the MRHD based on body surface devere advertam toxicity in some animas. A dose of 40 mg/kg (approximately equal to the MRHD on a mg/m2 basis) did not produce these effects. A similar study using articaine and epinephrine (1:100,000) rather than articaine hydrochloride alone produced maternal toxicity, but no effects on offspring. **8.3 Nursing Mothers** 

epinephrine (1:100,000) rather than articaline nyurocruonue annie province in a structure in the province in t

afety and effectiveness of articaine HCI 4% with epinephrine 1:200,000 and 1:100,000 in pediatric patients below the age of 4 years Salety and ellectrateries of allocate FiG1 + 8 with epidephile FL20000 and FIG0000 in potalarity patients between the ages of 4 and have not been established. Salety and effectiveness was established in clinicial trials with 61 pediatric patients between the ages of 4 and 16 years administered another product containing articaine hydrochoride 4% and epinephrine 1:100,000 injections. Filty-one of these patients received doses from 0.70 mg/kg 0.5 mg/kg 0.9 mL to 5.1 mL) of articaine HCI for simple dental procedures and 10 patients received doses between 0.37 mg/kg and 7.48 mg/kg 0.7 mL to 3.9 mL) of articaine HCI for simple dental procedures. Approximately 13% of these pediatric patients required additional injections of anesthetic for complex dental procedures. Approximately 13% of these pediatric patients required additional injections of anesthetic for complex dental procedures. Approximately 13% of these pediatric patients required additional injections of anesthetic for complex dental procedures. Approximately estimates with age, body weight, and physical condition [see Dosage and Administration (2.2)].

8.5 Geriatric Use

۲


commensurate with age, body weight, and physical conduloting bee Losage and Administration (2.2)). 8.3 Geriatric Use In clinical trials, 54 patients between the ages of 65 and 75 years, and 11 patients 75 years and over received another product containing articaine and expinption 1:100,000. Among all patients between 65 and 75 years, and over received another product containing articaine and expinption 1:100,000. Among all patients between 65 and 75 years, and over received another product containing articaine and expinption 1:100,000. Among all patients between 65 and 75 years, Among the 11 patients 75 years old, doeses from 0.78 mg/kg to 4.76 mg/kg (1.3 m. Lto 15,1 mL) of articaine HCI were safely administered safely to 7 patients for simple procedures. Approximately 6% of patients between the ages of 65 and 75 years and nore of the 11 patients 75 years old, doeses from 0.78 mg/kg to 4.76 mg/kg (1.3 m. Lto 15,1 mL) of articaine HCI were safely administered to 4 patients for complex procedures. Approximately 6% of patients between the ages of 65 and 75 years and none of the 11 patients 75 years of age or older required additional injections. No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. 8.8 Renal/Hepatic Insucciency No studies have been performed with articaine hydrochloride 4% and epinephrine 1:200,000 injection or articaine hydrochloride 4% and epinephrine 1:200,000 injection or articaine hydrochloride 4%, and epinephrine 1:100,000 injection in patients with renal or hepatic dysfunction [see Warnings and Precautions (5.2)]. 10 OVERDOSAGE

10 OVERDOSAGE


10 OVERDOSAGE Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution [see Warnings and Precautions (5.1, 5.2)]. The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient's state of consolutioness after each local anesthetic injection. At the first sign of change, oxygen should be administered. The first step in the management of convulsions, as well as hypo-ventilation, consists of immediate attention to the maintenance of a patent alway and assisted or controlled ventilation as needed. The adequacy of the circulation should be assessed. Should convulsions persist despite adequate respiratory support, treatment with appropriate anticonvulsant therapy is indicated. The practitioner should be familiar with the use of anticonvulsant drugs, prior to the use of local anesthetic injections. Supportive freatment of circulatory depression may require administration of intravenous fluids and, when appropriate, a vasopressor. If not treated immediately, both convulsions and cardiovascular depression can result in hypoxia, acidosis, bradycardia, arrhythmias, and/or cardiac arrest. If cardiac arrest should occur, standard cardiopulmonary resuscitative measures should be instituted. For additional information about overdose treatment, call a poison control center (1-600-722-1222). center (1-800-222-1222)



TO DESORMETION Orabio@injection is a sterile, aqueous solution that contains articaine HCI 4% (40mg/mL) and epinephrine bitartrate in an epinephrine 1:200,000 or epinephrine 1:100,000 strength. Articaine HCI is an amino amilo local anesthetic, chemically designated as 4-methyl-3-[2-(propylamino)- propionamido]-2-thiophene-carboxylic acid, methyl ester hydrochloride and is a racemic mixture. Articaine HCI has a molecular weight of 320.84 and the following structural formula:



r Articaine HCI has a partition coefficient in n-octanol/Soerensen buffer (pH 7.35) of 17 and a pKa of 7.8. Epinephrine bitartrate, (-)-1-(3,-4ihy/droxyphenyl)-2-methylamino-ethanol (+) tartrate (1:1) sall, is a vascconstrictor that is added to articaine HCI in a concentration of 1:200,000 or 1:100,000 (expressed as free base). It has a molecular weight of 333.3 and the following structural formula:



Orabloc® contains articaine HCI (40 mg/mL), epinephrine (1:200,000 or 1:100,000) (as epinephrine bitartrate) sodium chloride (1.0 mg ml) sodium metabisulfite (0.5 mg/ml) and water for injection. The product is formulated with a 10% overage of epinephrine. The pH is liusted to 3.6 with hydrochloric acid.

### 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action

Articaine HCI is an amide local anesthetic. Local anesthetics block the generation and conduction of nerve impulses, presumably b Increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of the affected nerve fibers. Epinephrine is a vasoconstrictor added to articaine HCI to slow absorption into the general circulation and thus no maintenance of an active tissue concentration

### 12.2 Pharmacodynamics

12.2 Pharmacodynamics Clinically, the order of loss of nerve function is as follows: (1) pain; (2) temperature: (3) touch; (4) proprioception; and (5) skeletal muscle tone. The onset of anesthesia has been shown to be within 1 to 9 minutes of injection of Orabloc®. Complete anesthesia lasts approximately 1 hour for infiltrations and up to approximately 2 hours for nerve block. Administration of Prabloc® results in a 3 to 5-fold increase in plasma expine/hine concentrations compared to baseline; however, in healthy adults it does not appear to be associated with marked increases in blood pressure or heart rate, except in the case of accidental intravascular injection [see Warnings and Depending (5 11).

lasts approximately 1 hour for infiltrations and up to approximately 2 hours for nerve block. Administration of OrabioOB results in a 3- to 5-fold increase in plasma epinephrine concentrations compared to baseline; however, in healthy adults it does not appear to be associated with marked increases in blood pressure or heart rate, except in the case of accidental intravascular injection [see Warnings and Precautions (5.1)]. **12.3 Pharmacokinetics Absorption:** Following dental injection by the submucosal route of an articaine solution containing epinephrine 1:20,000, articaine reaches peak blood concentrations about 25 minutes after a single dose injection and 48 minutes after three doses. Peak plasma levels of articaine encived after 68 mg and 204 mg doses are 385 ng/mL and 900 ng/mL, respectively. Following introard administration of an ear maximum dose of 476 mg, articaine reaches peak blood concentrations do 2037 ng/mL, and 2145 ng/mL for articaine solution containing epinephrine 1:00,000 and 1:200.000, respectively, approximately 22 minutes post-dose. **Distribution:** Aproximately 60% to 60% of articaine HC is bound to human serum albumin and y-globulins at 37°C in vitro. **Metabolism:** Articaine HCI is metabolized by plasma carboxysetrase to its primary metabolite, articaine as and with is inactive. In vitro studies show that the human liver microsome P450 isoenzyme system metabolizes approximately 5% to 10% of available articaine with nearly quantifiative conversion to articainic acid. **Excretion:** Afte dose of 476 mg of articaine, the elimination half-life was 43.8 minutes and 4.4 minutes for articaine solution containing epinephrine 1:00,000 and 1:200.000, respectively. Articaine is excreted primarily through urine with 53% to 57% of the 30 minutes and dose eliminated in the first 4 buors following submucosal administration. Articaine constitutes only 5% to 15% of 57% of the administered dose eliminate in the minutes the reharmoschinelics of OrabioOB injection in gelatric subjects. There is instifi

13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to evaluate the carcinogenic potential of articaine HCI in animals have not been conducted. Five standard mutagenicity tests, including three in vitro tests (the nonmammalian Ames test, the mammalian Chinese hamster ovary chromosomal aberration test, and a mammalian gene mutation test with articaine HCI) and two in vivo mouse micronucleus tests (one with articaine and epinephrine 1:000,000 and one with articaine HCI alone) showed no mutagenic effects. No effects on male or female fertility were observed in rats for articaine and epinephrine 1:100,000 administered subcutaneously in doses up to 80 mg/kg/day (approximately 2 times the MRHD bend an bedruin the news face area).

14 CLINICAL STUDIES

Another product containing articaine with epinephrine 1:100,000 was studied in three randomized, double-blind, active-controlled trials Another judgud Canadre winn generating en under generating in the second of the second to the operation of an entropy of the solution increases solution as single incomplicated in the increases and or bridge procedures, multiple converse more procedures, multiple converse and/or bridge procedures is untiple converse and/or bridge procedures by having the patient and investigator rate the patient's procedure planusing a 10 cm visual analog scale (VAS), in which a score of zero represented no patient and investigator rate the patient's procedure planusing a 10 cm visual analog scale (VAS), in which a score of zero represented no ariange in procedures and 0.5 cm-0.6 cm for complex procedures. Articatine with epinephrine 1:100,000 was also studies used lectric pulp testers (EPT) to evaluate the success rate (maximum EPT value within 10 minutes), onset, and duration of articatine containing epinephrine 1:100,000 versus articatine containing epinephrine 1:200,000 and atricatine solution without epinephrine 1:200,000 cmulations were not significantly different. A third study compared the difference in visualization of the surgical field after administration of articatine containing 1:100,000 epinephrine trading (1:100,000 epinephrine versus articatine containing 1:100,000 epinephrine the surgical field after examples in patient and investigation of the surgical field after administration of articatine containing 1:100,000 epinephrine versus articatine containing 1:100,000 epinephrine tradications of the surgical field after the surgical field after evaluation of articatine containing the procedures. In a fourth subuty, designed to assess and compare cardiovascular safety, when the maximum dose of each formulation were diserved.

tormulations were coserved. 15 REFERENCES Kaplan, EL, editor. Cardiovascular disease in dental practice. Dallas; American Heart Association; 1986. 16 HOW SUPPLIEDISTORAGE AND HANDLING Orabloc® (articaine HCI and epinephrine) Injection is available in 1.8 mL single use glass cartridges, packaged in boxes of 50 and 100

- OrabiOs (alticular for alto epineprinie) injection is available in 1.6 inc single use glass canadges, packag artifidges in the following two strengths: Orabios® containing articane HCI 4% and epinephrine 1:200,000 (NDC 45146-120-02 (50 cartridges/box)), NDC 45146-120-11 (100 cartridges/box)) Orabios® containing articaine HCI 4% and epinephrine 1:100,000 (NDC 45146-110-02 (50 cartridges/box), NDC 45146-110-01 (100 cartridges/box)) Soth products are formulated with a 10% overage of epinephrine.

### torage and Handling

Storage and Handling Store at 25° (C17°F) with brief excursions permitted between 15° and 30°C (59°F-86°F) [see USP Controlled Room Temperature]. Protect from light. Do Not Freeze. For chemical disinfection of the carpule, either isopropyl alcohol (91%) or ethyl alcohol (70%) is recommended. Many commercially available brands of isopropyl (rubbing) alcohol, as well as solutions of ethyl alcohol not of U.S.P. grade, contain denaturants that are injurious to rubber and therefore are not to be used. Parenteral drug products should be inspected visually for particulate matter and discoloration 17 PATIENT COUNSELING INFORMATION Loss of Sensation and Muscle Function: ation prior to administration, whenever solution and container permi

Inform patients in advance of the possibility of temporary loss of sensation and muscle function following infiltration and nerve block injections [see Adverse Reactions (6.2)]. Instruct patients not to eat or drink until normal sensation returns.

Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to stop use and seek immediate medical attention if they or someone in their care experience the following signs or symptoms: patients or caregivers to stop use and seek immediate medical attention if they or someone in their care experience the following signs or symptoms: patients due colored sin (capanosis); headacher, rapid heart rate; shorthess of breakth, lightheadechess; or fatgue.

Manufactured in Italy by: Pierrel S.p.A. - Strada Statale Appia 46/48 - 81043 Capua (CE), Italy

Revisided: 11/2018 00710723-02

## Please see accompanying full prescribing information or visit www.orabloc.com using the QR code.

To learn more about Orabloc call Pierrel at 1-610-989-4222 or email to orabloc@pierrelgroup.com



# THE QUALITY THAT YOU NEED, THE PRICE THAT YOU WANT





# **Orabloc**<sup>®</sup>

(articaine HCI 4% and epinephrine 1:100,000 and epinephrine 1:200,000) Injection



# **Orabloc**<sup>®</sup>

## Articaine HCI 4% and epinephrine 1:100,000 and epinephrine 1:200,000. Injection.

- » Rapid onset of anesthesia within 1-9 minutes
- » Complete anesthesia lasts about 1 hour for infiltrations, up to 2 hours for nerve block
- » 10% overage of epinephrine<sup>1</sup>
- » 24 month shelf life at room temperature

- » Each cartridge is sealed individually in the blister for maximum protection

## Orabloc is indicated for local, infiltrative, or conductive

- epinephrine 1:200,000 is preferred
- visualization of the surgical field are required. Orabloc containing epinephrine 1:100,000 may be used

## Both Orabloc strengths have a 24 month shelf life

- » Store at room temperature; 25°C (77°F), with brief excursions permitted between 15°C (59°F) and 30°C (86°F)
- » Protect from light
- » Do not freeze

۲

## **Orabloc** packaging

- » Each cartridge is individually sealed for maximum protection up to the moment of use
- » Cartridges packed 10 to a blister tray to avoid glass to glass contact
- » Blister trays packaged in boxes of 50

## **Dosage and administration – Adults**

- » For normal healthy adults, the maximum dose of Orabloc administered by submucosal infiltration and/or nerve block should not exceed 7mg/kg (0.175 mL/kg) of articaine HCI
- » Dosage should be reduced in elderly patients and in patients with cardiac or liver disease

## Pediatric patients ages 4 to 16 years

- » The quantity of Orabloc in children ages 4 to 16 years of age to be injected should be determined by the age and weight of the child and the magnitude of the operation
- » The maximum dose of Orabloc should not exceed 7 mg/ kg (0.175 mL/kg) of articaine HCI (see Use in Specific Populations). Use in pediatric patients under 4 years of age is not recommended

<sup>1</sup>The American Heart Association (AHA) recommends using the lowest possible quantity of epinephrine (Kaplan EL ed. Cardiovascular disease in dental practice. Dallas, TX: American Heart Association, 1986)

Capua (CE), Italy

Manufactured in Italy by: Pierrel S.p.A.

Strada Statale Appia 46/48 - 81043



## **IMPORTANT SAFETY INFORMATION**

Care should be taken to avoid accidental intravascular injection, which may be associated with convulsions followed by coma and respiratory arrest. Local anesthetic solutions that contain a vasoconstrictor should be used cautiously, especially in patients with impaired cardiovascular function or vascular disease. Administration of Orabloc results in a 3 to 5 fold increase in plasma epinephrine concentrations compared to baseline. However, in healthy adults it does not appear to be associated with marked increases in blood pressure or heart rate, except in the case of accidental intravascular injection. The most common adverse reactions (incidence >2%) are headache and pain. Inform patients in advance of the possibility of temporary loss of sensation and muscle function following infiltration and nerve block injections. Instruct patients not to eat or drink until normal sensation returns.

Please see accompanying full prescribing information or visit www.orabloc.com

Orablocis an amide local anesthetic containing a vaso constrictor indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures. Orabloc contains sodium metabisulfite. Orabloc is contraindicated in patients who are hypersensitive to products containing sulfites. Products containing sulfites may cause allergic-type reaction including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Please to see or download the full prescribing information visit www.orabloc.com

## PRESCRIBING INFORMATION **HIGHLIGHTS**

## HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORABLOC® safely and effectively. See full prescribing information These highlights de for ORABLOC®. tor OrABLOUE. Orabloc® (articaine HCI and epinephrine) Injection, Intraoral Submucosal Injection Articaine hydrochloride 4% and epinephrine 1:200,000 Articaine hydrochloride 4% and epinephrine 1:100,000

Initial II S Approval: 200

RECENT MAJOR CHANGES

## INDICATIONS AND USAGE

۲

aining a vasoconstrictor indicated for local, infiltrative, or conductive anesthesia in both simple AGE AND ADMINISTRATION

DOSAGE AND ADMINISTRATION For dental injection by submucosal infiltration and/or nerve block (2.1): • For infiltration: 0.5 mL-2.5 mL (20 mg-100 mg articaine HCI) (2.1) • For nerve block 0.5 mL-3.4 mL (20 mg-136 mg articaine HCI) (2.1) • For oral surgery: 1 ml-5.1 mL (40 mg-204 mg articaine HCI) (2.1) • For most routine dental procedures, Orabloc® containing geinephrine 1:200,000 is preferred. However, when more pronounced homeostasis or improved visualization of the surgical field are required, Orabloc® containing epinephrine 1:100,000 may be used. (2.1) • Dosages should be reduced in pediatric patients, elderly patients, and patients with cardiac or liver disease. (2.1) Maximum recommended dosages (2.2): Adults. 7 mg/kg (0.175 mL/kg) Children 4-16 years and adults. 7 mg/kg (0.175 mL/kg), depending on the new uncided meanshifted of the caregoriem age, weight and magnitude of the operation DOSAGE FORMS AND STRENGTHS

Injection (clear colorless solution), containing: - Articaine hydrochloride 4% (40 mg/mL) and epinephrine 1.200,000 (as epinephrine bitartrate 0.009 mg/mL) (3) - Articaine hydrochloride 4% (40 mg/mL) and epinephrine 1.100,000 (as epinephrine bitartrate 0.018 mg/mL) (3)

## CONTRAINDICATIONS

Known hypersensitivity to sulfite (4) WARNINGS AND PRECAUTIONS

 Methemoglobinemia: Cases of methemoglobinemia have been reported in association with local anesthetic use. (5.4)
Acoidental intravascular injection: May be associated with convulsions followed by coma and respiratory arrest. Resuscitative equipment, oxygen and other resuscitative drugs should be available. (5.1) Systemic Toxicity (5.2)

### Systemic loxicity (5.2) Vasoconstrictor Toxicity: Local anesthetic solutions like Orabloc® that contain a vasoconstrictor should be used cautiously, especially in patients with impaired cardi vascular function or vascular disease. (5.3)

## Anaphylaxis and Allergic-Type Reactions (5.5) ADVERSE REACTIONS

erse reactions (incidence >2%) are headache and pain (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Pierrel S.p.A. at 610-989-4213 or FDA at 1-800-FDA-1088 or

- DRUG INTERACTIONS
- vitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine (7) USE IN SPECIFIC POPULATIONS

SE IN SPECIFIC POPULATIONS Pregnancy: Based on animal studies, may cause fetal harm (8.1) • Nursing Mothers: Exercise caution when administering to a nu woman (8.3) • Pediatric Use: Safety and effectiveness in pediatric patients below the age of 4 years have not been established See 17 for PATIEINT COUNSELING INFORMATION Revised: 11/2018

## FULL PRESCRIBING INFORMATION: CONTENTS\*

## 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2 1 General Dosing Information 2.2 Mi 2.1 General Dosing Information 2.2 Maxin 3 DOSAGE FORMS AND STRENGTHS CONTRAINDICATIONS WARMING mended Dosages 2.3 Dosing in Special Population 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Accidental Intravascular Injection

cular Injection 5.2 Systemic Toxicity 5.3 Vasoconstrictor Toxicity 5.4 Methemoglobinemia 5.5 Anaphylaxis and Allergic-Type Reactions 6 ADVERSE REACTIONS

perience 6.2 Postmarketing Experience

7 DRUG INTERACTIONS 8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Renal/Hepatic Insufficiency 10 OVERDOSAGE

11 DESCRIPTION 12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION

\*Sections or subsections omitted from the full prescribing information are not listed

### FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

Body system/Reaction Body as whole Face edema - 13 (1%) Orabloc® is an amide local anesthetic containing a vasoconstrictor indicated for local, infiltrative, or conductive anesthesia in both simple Infection - 10 (1%) Pain - 114 (13%) 2.1 General Dosing Information Digestive system Gingivitis - 13 (1%) ded volumes and concentrations of Orabloo® for various types of anesthetic procedures. The ges suggested in this table are for normal healthy adults, administered by submucosal infiltration or nerve block Nervous system Paresthesia - 11 (1%) Table 1: Recommended Dosages for Both Strengths Table 3: Adverse Reactions in Controlled Trials with an Incidence of 1% or Greater in Patients Administered articaine containing epinephrine 1:200,000 and articaine containing epinephrine 1:100,000 (Neaton - articaine with epinephrine 1:200,000 (N=182) Any adverse event - 33 (18%) - 55 (19%) Pain - 11 (6.1%) - 54 (7.6%) - 55 (19%) Pain - 11 (6.1%) - 14 (7.6%) - 55 (19%) Procedure Orabloc® Injection Infiltration - Volume (mL) 0.5 m. Ito 2.5 mL - Total dose of articaine HCI (mg) 20 mg to 100 mg Norve block - Volume (mL) 0.5 mL to 3.4 mL - Total dose of articaine HCI (mg) 20 mg to 136 mg Oral surgery - Volume (mL) 1 mL to 5.1 mL - Total dose of articaine HCI (mg) 40 mg to 204 mg The recommended doses serve only as a guide to the amount of anesthetic required for most routine procedures. The actual volumes to be used depend on a number of factors such as type and extent of surgical procedure, depth of anesthesia, degree of muscular relaxation, and condition of the patient. In all cases, the smallest dose that will produce the desired result should be given. The onset of anesthesia and the duration of anesthesia are proportional to the volume and concentration (i.e., total dose) of local anesthetic used. Caution should be exercised when employing large volumes because the incidence of side effects may be dose-related. For most routine dental procedures, Orabloo® containing epinephrine 1:200,000 is preferred. However, when more pronounced hemostasis or improved visualization of the surgical field are required, Orabloo® antiming epinephrine 1:100,000 may be used. **2.1 Maximum Recommended Dosages** 4 Adults. For normal healthy adults, the maximum dose of Orabloo® administered by submucosal infiltration and/or nerve block should not exceed 7 mg/kg (0.175 m.l/kg) of articaine HCL · Pediatric Patients Ages 4 to 16 Veras: The quantity of Crabloo® in children ages 4 to 16 years of age to be injected should be determined by the age and weight of the child and the magnitude of the operation. The maximum dose of Orabloo® in pediatric patients below the age of 4 years have not been established. **2.3 Dosing in Special Populations** eadache - 9 (5%) - 6 (3.2%) Positive blood aspin ringe - 3 (1.6%) - 6 (3.2%) Swelling - 3 (1.6%) - 5 (2.7%) Trismus - 1 (0.3%) - 3 (1.6%) Nausea and emesis - 3 (1.6%) - 0 (0%) Sleepiness - 2 (1.1%) - 1 (0.5%) Numbness and tingling - 1 (0.5%) - 2 (1.%) Palpitation - 0 (0%) - 2 (1.%)

and encoveness of urbandoor in pediatric patients below the age of 4 years have not been estationshed. 23 Dosing in Special Populations Dose reduction may be required in debilitated patients, acutely ill patients, elderly patients, and pediatric patients commensurate with their age and physical condition. No studies have been performed in patients with renal or liver dysfunction. Caution should be used in patients with severe liver disease. [see Warnings and Precoutions (5.2), Use in Specific Populations (8.4, 8.5, and 8.6)] 3 DOSAGE FORMS AND STRENGTHS

Injection (clear colorless solution), containing: - Articaine hydrochloride 4% and epinephrine 1:200,000 (as epinephrine bitartrate 0.009 mg/mL) - Articaine hydrochloride 4% and epinephrine 1:100,000 (as epinephrine bitartrate 0.018 mg/mL) 4 CONTRAINDICATIONS

4 CONTRAINDUCATIONS Orabloc® is contraindicated in patients who are hypersensitive to products containing sulfites. Products containing sulfites may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people (see Warnings and Precautions (5.5)).

- » Sodium edetate free, methylparaben free and latex free
- » Most common adverse reactions (incidence >2%) are headache and pain

## anesthesia in both simple and complex dental procedures:

» For most routine dental procedures, Orabloc containing

## » When more pronounced homeostasis or improved

## 5 WARNINGS AND PRECAUTION

SWARNINGS AND PRECAUTIONS
5.1 Accidental Intravascular Injection
Accidental Intravascular injection of Orabioo® may be associated with convulsions, followed by central nervous system or cardiorespiratory
depression and coma, progressing ultimately to respiratory arrest. Dental practitioners who employ local aneshetic agents including
Orabioo® should be well verse in diagnosis and management of emergencies that may arise from their use. Resuscitative equipment,
oxygen, and other resuscitative drugs should be available for immediate use. To avoid intravascular injection, note, however, that the
absence of blood in the syninge does not guarantee that intravascular injection has been avoided. Small doese of local aneshetics injected
in dental bloots may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injection of large doese.
Confusion, convulsions, respiratory depression and/or respiratory arrest, and cardiovascular singleton of larger doese.
Confusion, convulsions, respiratory depression and/or respiratory arrest, and cardiovascular singletons of larger doese.
Confusion, convulsions, respiratory depression and/or respiratory arrest, and cardiovascular singletion or been reported.
These reactions may be due to intra-articlar linection of the local aneshetic with retrograde flow to the cerebral circulation.
Patients receiving
these bloots should be observed constantly. Resuscitative equipment and personnel for treating adverse reactions should be immediately
available. Dosage recommendations should not be exceeded [see Dosage and Administration [2, 1]):
**5.2 Systemic Toxicity** This includes toxicity aring from accidental intravascular injection of Orabloo® discussed in Section 5.1, as well as that related to

This includes toxicity arising from accidental intravascular injection of Orabloc® discussed in Section 5.1, as well as that related to This model backs straining with recommendation interfaces of the second straining and straining an ead to atrioventricular block, ventricular arrhythmias, and cardiac arrest, possibly resulting in fatalities. In addition, myocardial contractilit s depressed and peripheral vasodilatation occurs, leading to decreased cardiac output and arterial blood pressure. Orabloc® should also be used with caution in patients with heart block as well as those with impaired cardiovascular function since they may be less able to compensate for functional changes associated with the prolongation of A-V conduction produced by these drugs. Restlessness anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of central nervous syster toxicity. Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient's state of consciousness should be performed after each local anesthetic injection of Orabloc®. Repeated doses of Orabloc® may cause significant incre eases in blood levels because of possible accumulation of the drug or its metabolites. The lowest dosage that results significant increases in loade evers because or possible additionation or the drug or its meadoutes. The lowes tobage that results in effective anesthesia should be used to decrease the risk of high plasma levels and serious adverse effects. Tolerance to elevate blood levels varies with the status of the patient. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. Precautions for epinephrine administration, discussed in Section 5.3 should be observed. Debilitated patients, elderly

blood levels varies wint me status of the patient. Nesuscitative equipment, oxygen, and other resuscitative drugs should be available tor immediate use. Precautions for eignephrine administration, discussed in Section 5.3 should be observed. Debilitated patients, elderly patients, acutely ill patients, and pediatric patients should be given reduced doese commensurate with their age and physical condition (see Dosage and Administration (2.1, 2.3)). No studies have been performed in patients with liver dysfunction, and caution should be used in patients with severe hepatic disease. **5.3 Vasoconstrictor Toxicity** Orabloo® contains epinephrine, a vasoconstrictor that can cause local or systemic toxicity and should be used cautiously. Local toxicity may include ischemic nignry or necrosis, which may be related to vascular spasm. Orabloo® should be used cautiously. Local toxicity may include ischemic nignry or necrosis, which may be related to vascular spasm. Orabloo® should be used with acution in patients during or following the administration of potent general aneshetic agents, since cardiac arrivythmism may occur under such conditions. Patients with peripheral vascular disease and those with hypertensive vascular disease may exhibit exaggerated vasoconstrictor response. The American Heart Association has made the following recommendation regarding the use of local anesthetics with vasoconstrictor since antions in patients is clear that the procedure will be shortened or the analgesia rendered more profound. When a vasoconstrictor is indicated, extreme care should be easen to avoid intravascular injection. The minimum possible amount of vasconastrictor should be used." (Kaplan, 1986). It is essential to aspirate before any injection to avoid administration of the drug into the blood stream. **5.4 Methemoglobinemia** 

taken to avoid intravascular injection. The minimum possible amount or vasioonisticior should be used: (xapian, 1966), it is essential to aspirate before any injection to avoid administration of the drug into the blood stream. **5.4 Methemoglobinemia** (avoid administration of the drug into the blood stream. **5.4 Methemoglobinemia** have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary comprovise, inflants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, coles monitoring for symptoms and signs of methemoglobinemia is recommended. Signs and symptoms of methemoglobinemi may occur immediately or may be delayed some hours after exposure, and are characterized by a cynotics kin discoloration and abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue ORABLOC and any other oxidizing agents. Depending on the severity of the symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. More severe symptoms may require treatment with methylene blue, exchange transfusion, or hypertaric oxygen. Orablood, like other local anesthetic solutions containing a vasoconstrictor, can cause methemoglobinemia, particularly in conjunction with methemoglobin-inducing agents. Crabloo® should not be used in patients with congenital or idiopathic methemoglobinemia and undued methemoglobinemia and symptoms of methemoglobinemia may be delayed some hours after exposure. Initial signs and symptoms may include central cyanosis, headache, lethargy, dizzine Jobinemia should be treated with administration of a slow intravenous injection (over 5 minutes) of methylene blue at a of methemo

of methemoglobinemia should be treated with automissioned to be added and a state of 1-2 mg/kg body weight. 5.5 Anaphylaxis and Allergic-Type Reactions Orabloo® contains sodium metabisulfite, a suffite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of suffite sensitivity in the general population is unknown. Suffite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.

ADVERSE REACTIONS Reactions to articaine are characteristic of those associated with other amide local anesthetics. Adverse reactions to this group of drugs may also result from excessive plasma levels (which may be due to overdosage, unintentional intravascular injection, or slow metabolic degradation), injection technique, volume of injection, or hypersensitivity or they may be idiosyncratic. 6.1 Clinical Studies Experience Because clinical trials are durated under widely varying conditions, adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in practice. The reported adverse events are derived from clinical trials in the United States and the United Kingdom with a similar product containing articaine and epinephrine. Table 2 displays the adverse events reported in clinical trials where 882 individuals were exposed to articaine containing epinephrine 1:100.000. Table 3 displays the adverse events reported in clinical trials where 882 individuals were exposed to articaine containing epinephrine 1:100.000 and 179 individuals were exposed to articaine containing epinephrine 1:100,000 and 179

## Table 2: Adverse Reactions in Controlled Trials with an Incidence of 1% or Greater in Patients Adm

tion - articaine containing epinephrine 1:100,000 (N=882) Incidenc

Ear symptoms (earache, otitis media) - 1 (0.5%) - 2 (1.%) ough, persistent cough - 0 (0%) - 2 (1.%) dverse reactions observed in less than 1% of patients:

Table 4: Adverse Reactions in Controlled Trials with an Incidence of Less than 1% but Considered Clinically Relevant

Body System - Events Body as a Whole - Asthenia; back pain; injection site pain; burning sensation above injection site; malaise; neck pain Cardiovascular System - Hemorthage; migraine; syncope; tachycardia; elevated blood pressure Digestive System - Dyspepsia; glossitis; gum hemorthage; mouth ulceration; nausea; stomatitis; tongue edemas; tooth disorder; vomiting Hemic and Lymphatic System - Echymosis; tymphadenopathy Metabolic and Nutritional System - Edema; thirst Musculoskeletial System - Arthratigia; malajia; osteomyelliis Nervous System - Dizzines; dy mouth; facial paralysis; hypersthesia; increased salivation; nervousness; neuropathy; paresthesia; somnolence; exacerbation of Keams-Sayre Syndrome Respiratory System - Pharyngiis; hinhis; sinus pain; sinus congestion Skin and Appendages - Pruritus; skin disorder Special Senses - Ear pain; taste perversion